Real‐World Performance of a Novel Wearable Cardioverter‐Defibrillator System: Primary Results From a National Prospective Post‐Approval Registry Study (ACE‐PAS)
ABSTRACT Introduction Wearable cardioverter defibrillators (WCDs) protect patients at elevated risk of sudden cardiac death (SCD) but are effective only when worn. The ASSURE WCD was designed to address historical limitations related to false alarms and patient adherence. The objective of this post‐approval study was to assess safety and effectiveness in a large, real‐world cohort. Methods The study population was comprised of patients meeting WCD indications who were fitted with the ASSURE WCD. The primary effectiveness endpoint was overall shock conversion success for ventricular tachycardia (VT) or ventricular fibrillation (VF) (performance goal ≥ 89%), and the primary safety endpoint was the incidence of inappropriate shocks (performance goal ≤ 0.0075 per patient‐month). Results Among 21 612 patients (mean age 64.0 years, 33.9% female), median daily use was 23.1 h/day (IQR 16.1–23.9) over 54 days (IQR 20–97). WCD indications included cardiomyopathy (63.8%), post‐myocardial infarction (19.3%), sustained VT/VF (11.9%) and ICD explant/other (5.0%). Both primary effectiveness and safety endpoints were met. All 303 VT/VF shock events in 261 patients (1.2%) were successfully converted, yielding an overall shock conversion success of 100% (95% CI: 98.8%–100%), with first‐shock success of 97.0% (95% CI: 94.4%–98.5%). The incidence rate of inappropriate shocks was 0.0065 per patient‐month (95% CI: 0.0057–0.0073). False‐positive alarms occurred in 6.0% of patients. The 90‐day Kaplan–Meier estimated risk of VT/VF was 3.4%, varying by WCD indication ( p < 0.001) but not by left ventricular ejection fraction ( p = 0.16). Conclusion In routine practice, the ASSURE WCD effectively terminated VT/VF with low false alarm and inappropriate shock rates and high patient adherence. Most VT/VF events occurred early during WCD wear. Collectively, these findings provide important contemporary evidence to inform the selection of patients who may benefit from WCD therapy during periods of elevated arrhythmic risk. Trial Registration NCT05135403.
Authors
- Kelley R. Branch (ORCID: https://orcid.org/0000-0003-2362-6498)
- Arun Raghav Mahankali Sridhar (ORCID: https://orcid.org/0000-0002-0608-5901)
- Ulrika Maria Birgersdotter-Green (ORCID: https://orcid.org/0000-0002-0473-1826)
- Rahul N. Doshi (ORCID: https://orcid.org/0000-0001-5555-7672)
- Jeanne E. Poole (ORCID: https://orcid.org/0000-0002-8481-7389)
- Laura M. Gustavson (ORCID: https://orcid.org/0000-0002-8212-3762)
- Wayne C. Levy (ORCID: https://orcid.org/0000-0003-1530-2194)
- Marye J. Gleva (ORCID: https://orcid.org/0000-0002-0755-6437)
- Shirley A. Zulueta
Institutions
- University of Washington (US)
- Washington University in St. Louis (US)
- University of California San Diego (US)
- HonorHealth (US)
Publication Details
- Journal
- Journal of Cardiovascular Electrophysiology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1111/jce.70556
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00